PUBLISHER: The Business Research Company | PRODUCT CODE: 1653151
PUBLISHER: The Business Research Company | PRODUCT CODE: 1653151
Nootropics, also known as smart drugs or cognitive enhancers, refer to substances that aim to enhance memory and cognitive function with a stimulant effect. These substances are utilized to boost brain performance and include caffeine, creatine, vitamins, and minerals. Nootropics are often used to increase memory, improve strength, or enhance other cognitive functions. It's important to note that while they may affect memory, thinking, or other mental functions, they do not treat diseases.
The main types of drugs categorized as nootropics include prescription nootropics and over-the-counter (OTC) nootropics. Prescription nootropics are often utilized to provide stimulant effects and may be prescribed to counteract symptoms associated with medical conditions such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, or narcolepsy. Nootropics are available in various forms, including capsules or tablets, powder, drinks, and others, and are distributed through multiple channels, both online and offline. They find application in memory enhancement, mood and depression treatment, attention and focus improvement, longevity and anti-aging efforts, sleep and recovery promotion, and anxiety treatment.
The nootropics market research report is one of a series of new reports from The Business Research Company that provides nootropics market statistics, including nootropics industry global market size, regional shares, competitors with a nootropics market share, detailed nootropics market segments, market trends and opportunities, and any further data you may need to thrive in the nootropics industry. This nootropics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nootropics market size has grown rapidly in recent years. It will grow from $5.23 billion in 2024 to $6.01 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to aging population, regulatory support, increased research and development, e-commerce expansion, rise in esports.
The nootropics market size is expected to see rapid growth in the next few years. It will grow to $11.46 billion in 2029 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing stress and cognitive demands, globalization, rising disposable incomes, rising mental health awareness, expansion of emerging markets. Major trends in the forecast period include natural and plant-based nootropics, digital nootropics, transcranial stimulation devices, sustainable and ethical sourcing, inndustry collaboration.
The rising investment in health and wellness is anticipated to drive the growth of the nootropics market in the future. Health and wellness are typically understood as approaches individuals take to achieve mental health and physical well-being. This encompasses a thorough exploration of the health and wellness industry. Nootropics play a significant role in supporting an individual's health and wellness; therefore, as the demand for healthcare and wellness rises, the need for nootropics will also increase. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, a significant increase compared to the 0.9% growth noted in 2022. Hence, the growing expenditure on healthcare and wellness is driving the nootropics market.
The rising incidence of lifestyle diseases is expected to drive the growth of the nootropics market in the future. Lifestyle diseases, commonly referred to as non-communicable diseases (NCDs) or chronic diseases, are a collection of health issues primarily resulting from unhealthy lifestyle choices and behaviors rather than infectious agents. Individuals suffering from lifestyle diseases such as obesity and diabetes often face cognitive decline, stress, and decreased energy levels. Nootropics are utilized to enhance cognitive abilities, manage stress, increase energy, and aid in weight management. For example, in September 2022, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that there were 41 million deaths annually worldwide, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases. This included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the rising prevalence of lifestyle diseases is propelling the growth of the nootropics market.
The popularity of vegan nootropics is increasing in the global nootropics market. Leading companies in the nootropics sector are pursuing new organic product innovations to satisfy consumer demand and maintain their market position. For example, in July 2022, BioAdaptives Inc., a US-based producer of natural supplements derived from plants and algae, introduced MindMemory, an advanced nootropic designed to enhance memory, mental focus, and concentration. This new product offers a gradual and smooth effect, unlike coffee, which can cause a sudden surge of adrenaline.
Leading companies in the nootropics market are creating multi-flavored nootropics to appeal to a diverse audience with different tastes and preferences. Multi-flavored nootropics are cognitive-enhancing supplements offered in various flavors to enhance taste appeal. For example, in June 2023, Rollagranola, a UK-based food and beverage company, launched a range of nootropics featuring four unique flavors aimed at addressing both nutritional requirements and taste preferences. This innovative lineup includes Calm, Energize, Body and Soul, and Complete Vegan. Calm is designed to promote relaxation and stress reduction with ingredients like ashwagandha and matcha green tea. Energize features a cappuccino and white chocolate blend to boost focus and energy, incorporating lion's mane, caffeine, and panax ginseng. Body and Soul combines summer berries and walnuts to support physical and mental well-being, using ingredients like creatine, maca, ginkgo, and panax ginseng. Finally, Complete Vegan is a granola specifically designed for vegans, offering essential nutrients, pea protein, and key vitamins to address deficiencies and enhance focus, memory, and mood.
In August 2024, Paradigm Sports, a US-based sports management services provider, formed a partnership with Ten Percent Club. This collaboration aims to educate athletes about the advantages of nootropics for enhancing cognitive performance while broadening product offerings in the sports industry to optimize mental preparation and recovery. The partnership seeks to redefine athlete performance through innovative cognitive support solutions. Ten Percent Club is a UK-based company that sells nootropic-based supplements, including Nootropics.
Major companies operating in the nootropics market include Accelerated Intelligence Inc., AlternaScript Inc. Health Via Modern Nutrition Inc., Mental Mojo LLC., Peak Nootropics, PureLife Bioscience Co. Ltd., TruBrain, PepsiCo, Superior Supplement Manufacturing, Equinox Nutraceuticals, Natural Stacks Inc., Gaia Herbs Farms., Kimera Koffee LLC., Onnit Labs LLC., Reckitt Benckiser Group plc., OUTLIERS INC., Teva Pharmaceutical Industries Ltd., United Pharmacies o, Clarity Nootropics, OptiMind, HVMN Inc., BioAdaptives Inc., Powder City
North America was the largest region in the nootropics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nootropics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nootropics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The nootropics market includes revenues earned by entities by modafinil (provigil), adderall, methylphenidate (ritalin), memantine (axura), caffeine, l-theanine, and omega-3 fatty acids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nootropics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nootropics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for nootropics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nootropics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.